ALLO — Allogene Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1737287 ·
Last close
$2.00
Market Cap
$690.31M
52W High
$4.46
52W Low
$1.75
ADV30
10,014,383
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -46,092,000 | -42,607,000 | 395,958,000 | 30,309,000 | 117,083,000 |
| Dec 2025 | 0 | — | -42,404,000 | -38,810,000 | 415,905,000 | 51,688,000 | 123,363,000 |
| Sep 2025 | 0 | — | -44,901,000 | -41,400,000 | 439,771,000 | 37,815,000 | 124,442,000 |
| Jun 2025 | 0 | — | -54,437,000 | -50,943,000 | 470,593,000 | 52,332,000 | 126,032,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-109,230,000
Investing CF
$59,795,000
Financing CF
$37,289,000
CapEx
$-395,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.77
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,053,316,000
Inventory
—
Receivables
—
ST Investments
$236,577,000
EBIT TTM
$-172,535,000
Pretax Income TTM
$-173,760,000
Interest Exp TTM
$1,225,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -206,933,000 | -190,886,000 | 415,905,000 | 123,363,000 | — | -149,246,000 |
| Dec 2024 | 22,000 | -257,482,000 | -257,590,000 | 548,710,000 | 126,531,000 | — | -200,300,000 |
| Dec 2023 | 95,000 | -314,492,000 | -327,265,000 | 642,837,000 | 130,604,000 | — | -237,733,000 |
| Dec 2022 | 156,000 | -335,536,000 | -340,414,000 | 821,579,000 | 154,697,000 | — | -220,519,000 |
TTM Snapshot
Revenues TTM
$120,000
NetIncome TTM
$-289,979,000
OpCashFlow TTM
$0
Assets (Latest)
$548,710,000
Forward EPS
$-0.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | $695.33M | $9.49 | — |
| PRME | Prime Medicine, Inc. | $682.73M | $3.78 | — |
| AURA | Aura Biosciences, Inc. | $707.51M | $6.84 | — |
| RGNX | REGENXBIO Inc. | $721.18M | $13.95 | — |
| TECX | Tectonic Therapeutic, Inc. | $648.53M | $34.37 | — |
News headlines (Yahoo Finance, 1h cache)
Kyverna Therapeutics Sinks 13%: Here’s Why
2026-07-10 19:59 · Yahoo
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions
2026-06-28 05:05 · Yahoo
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease
2026-06-17 15:17 · Yahoo
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
2026-06-12 15:30 · Yahoo
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio
2026-06-07 17:57 · Yahoo
Allogene Therapeutics Announces Planned CEO Succession
2026-05-28 21:02 · Yahoo
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
2026-05-26 12:30 · Yahoo
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
2026-05-14 14:17 · Yahoo
Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
2026-05-14 13:20 · Yahoo
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ...
2026-05-14 05:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.